{
    "organizations": [],
    "uuid": "4fbe99d605d8261fe7314d8c89dcaaa54d24e81a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-urogen-pharma-reports-q4-loss-per/brief-urogen-pharma-reports-q4-loss-per-share-of-0-74-idUSASC09SDY",
    "ord_in_thread": 0,
    "title": "BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 15, 2018 / 11:17 AM / Updated 8 minutes ago BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74 Reuters Staff March 15 (Reuters) - Urogen Pharma Ltd: * UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS * Q4 LOSS PER SHARE $0.74 * Q4 EARNINGS PER SHARE VIEW $-0.62 — THOMSON REUTERS I/B/E/S * ‍TOP-LINE DATA FROM OLYMPUS PIVOTAL TRIAL ARE EXPECTED IN Q3 2018.​ * ‍POTENTIAL APPROVAL AND COMMERCIAL LAUNCH OF MITOGEL IN UNITED STATES IS TARGETED FOR H2 2019​ * ‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALED $73.0 MILLION​ * ‍ ASSUMING POSITIVE RESULTS, PLANNED SUBMISSION OF NDA TO U.S. FDA IN Q1 2019 FOR MITOGEL​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-03-15T13:17:00.000+02:00",
    "crawled": "2018-03-15T13:38:52.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "pharma",
        "report",
        "q4",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "march",
        "reuters",
        "urogen",
        "pharma",
        "ltd",
        "urogen",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "data",
        "olympus",
        "pivotal",
        "trial",
        "expected",
        "q3",
        "approval",
        "commercial",
        "launch",
        "mitogel",
        "united",
        "state",
        "targeted",
        "h2",
        "december",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "totaled",
        "assuming",
        "positive",
        "result",
        "planned",
        "submission",
        "nda",
        "fda",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}